LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

Home・Listă Acțiuni・AstraZeneca PLC

AstraZeneca PLC

Închisă

SectorSănătate

187.25 -1.32

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

186.99

Maxim

188.07

Indicatori cheie
By Trading Economics
Venit	1.6B 3.9B
Vânzări	-215M 15B
P/E Medie Sector	27.887 49.701
EPS	1.29
Randament dividend	1.74
Marjă de profit	25.602
Angajați	96,100
EBITDA	1.1B 5.7B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+15.88% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	1.74% 2.39%
Următoarele câștiguri	27 iul. 2026
Următoarea dată ex-dividende	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-3.5B 287B
Deschiderea anterioară	188.57
Închiderea anterioară	187.25

AstraZeneca PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 16:28 UTC

Câștiguri

Correction to AstraZeneca Update

29 apr. 2026, 15:11 UTC

Câștiguri

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 apr. 2026, 06:31 UTC

Câștiguri

AstraZeneca Gets Revenue Boost From Cancer Drugs

21 mai 2026, 11:06 UTC

Market Talk

AstraZeneca Set for Busy End of Year -- Market Talk

13 mai 2026, 12:29 UTC

Market Talk

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 mai 2026, 11:54 UTC

Market Talk

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 mai 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 apr. 2026, 10:29 UTC

Market Talk

Câștiguri

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 apr. 2026, 10:06 UTC

Market Talk

Câștiguri

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 apr. 2026, 09:53 UTC

Market Talk

Câștiguri

AstraZeneca Seems in Fine Health -- Market Talk

29 apr. 2026, 06:05 UTC

Câștiguri

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 apr. 2026, 06:04 UTC

Câștiguri

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 apr. 2026, 06:04 UTC

Câștiguri

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 apr. 2026, 06:03 UTC

Câștiguri

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 apr. 2026, 06:03 UTC

Câștiguri

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 apr. 2026, 06:02 UTC

Câștiguri

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 apr. 2026, 06:01 UTC

Câștiguri

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 apr. 2026, 06:01 UTC

Câștiguri

AstraZeneca Backs 2026 View

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Adj EPS $2.58

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Rev $15.29B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Oper Pft $4.25B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q Net Pft $3.08B

29 apr. 2026, 06:00 UTC

Câștiguri

AstraZeneca PLC 1Q EPS $1.97

27 apr. 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 apr. 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 apr. 2026, 10:26 UTC

Market Talk

Câștiguri

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 apr. 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 mar. 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 mar. 2026, 10:17 UTC

Market Talk

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Comparație

Modificare preț

AstraZeneca PLC Așteptări

Obiectiv de preț

By TipRanks

15.88% sus

Prognoză pe 12 luni

Medie 216.733 USD 15.88%

Maxim 250.747 USD

Minim 152.335 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAstraZeneca PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 15 analiști care au acordat evaluări ale acțiunilor AstraZeneca PLC - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.